Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRXBiotechnology
-$0.01 today
- Market cap
- $3.85B
- Beta
- 0.74
- P/E (TTM)
- 17.3
- EPS (TTM)
- $1.81
Volume 0.00M
Average 2.17M
CPRX EBITDA Margin
EBITDA as a percentage of revenue.
Catalyst Pharmaceuticals, Inc.NASDAQ: CPRX
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to 63.0%
EBITDA Margin was 63.0% in Q1 FY2026, up 5.9 pp from a year earlier. On a trailing-twelve-month basis it was 56.1%, up 0.7 pp year over year. Over 3 fiscal years it widened by 5.1 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 45.0% for the fiscal year ending Dec 2026, down from 54.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 63.0%+9.6 pp QoQ
- Last fiscal yearDec 2025
- 54.6%+2.9 pp YoY
- LTMMar 2026
- 56.1%+0.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.9 pp | -8.7 pp | -14.6 pp |
| 1 year | +2.9 pp | -9.5 pp | -12.4 pp |
| 3 years | +5.1 pp | -9.5 pp | -14.6 pp |
| 5 years | -9.5 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 54.6%
- Year-over-year change
- +2.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 54.6% | +2.9pp |
| FY2024 | 2024-12-31 | 51.7% | +19.7pp |
| FY2023 | 2023-12-31 | 32.0% | -17.5pp |
| FY2022 | 2022-12-31 | 49.5% | +11.9pp |
| FY2021 | 2021-12-31 | 37.5% | — |
EBITDA Margin vs competitors
How CPRX compares with its peers on the latest reported figures
- CPRX's LTM Mar 2026 EBITDA Margin of 56.1% is the highest of the 8 companies compared; the peer median is -60.1%.
- Its year-over-year change of +0.7 pp is the 6th highest of 7, against a peer median of +68.8 pp.
- Over three fiscal years its change of +5.1 pp compares with a peer median of +72.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 56.1% | +0.7 pp | +5.1 pp | |
| LTM Jun 2026 | 13.3% | +10.4 pp | +7.2 pp | |
| LTM Jun 2026 | -5.2% | +42.1 pp | +83.8 pp | |
| LTM Jun 2026 | -40.5% | +584.3 pp | +435.7 pp | |
| LTM Mar 2026 | -60.1% | +4260.2 pp | +61.2 pp | |
| LTM Mar 2026 | -633.4% | -2566.2 pp | +811.4 pp | |
| LTM Jun 2026 | -810.2% | +95.5 pp | -175.3 pp | |
| LTM Sep 2026 | -69878.4% | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CPRX) | -60.1% | +68.8 pp | +72.5 pp | |
Competitors are the stored peer set for CPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 140.83M | 214.2M | 398.2M | 491.73M | 588.99M |
| Cost of Revenue | 21.88M | 34.39M | 51.97M | 68.85M | 87.25M |
| Gross Profit | 118.95M | 179.81M | 346.24M | 422.89M | 501.74M |
| Gross Margin | 84.5% | 83.9% | 86.9% | 86.0% | 85.2% |
| Research & Development | 16.94M | 19.79M | 93.15M | 12.65M | 12.71M |
| Selling, General & Admin | 49.63M | 57.09M | 133.71M | 177.74M | 193.75M |
| Operating Expenses | 66.56M | 77.97M | 259.43M | 227.77M | 243.96M |
| Depreciation & Amortization | 192K | 1.24M | 32.88M | 37.77M | 37.87M |
| EBITDA | 52.86M | 105.96M | 127.39M | 254.04M | 321.39M |
| EBITDA Margin | 37.5% | 49.5% | 32.0% | 51.7% | 54.6% |
| Operating Income | 52.39M | 101.84M | 86.81M | 195.12M | 257.78M |
| Operating Margin | 37.2% | 47.5% | 21.8% | 39.7% | 43.8% |
| Interest Income | 0 | 0 | 0 | 16.06M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 282K | 2.88M | 7.7M | 21.14M | 25.74M |
| Income Before Tax | 52.67M | 104.72M | 94.51M | 216.26M | 283.52M |
| Pre-Tax Margin | 37.4% | 48.9% | 23.7% | 44.0% | 48.1% |
| Income Tax Expense | 13.19M | 21.64M | 23.1M | 52.37M | 69.19M |
| Net Income | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M |
| Net Margin | 28.0% | 38.8% | 17.9% | 33.3% | 36.4% |
| EPS (Basic) | 0.38 | 0.80 | 0.67 | 1.38 | 1.75 |
| EPS (Diluted) | 0.37 | 0.75 | 0.63 | 1.31 | 1.68 |
| Weighted Avg Shares | 103.38M | 103.37M | 106.28M | 118.46M | 122.29M |
| Weighted Avg Shares (Diluted) | 107.8M | 111.38M | 113.75M | 124.94M | 127.26M |
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
Intrinsic Alpha fair value
Locked
Current Price
$31.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.